This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The screening strategy was compared against no screening, which represented the current pattern of care in the authors' setting. In the IDU cohort, screening included a HCV serology every 6 months lifelong. In the IWS cohort, two tests of serology for each patient were provided at time 0 and after 6 months.
Location/setting
Italy. Primary care/hospital.
Methods

Analytical approach:
This economic evaluation was based on a Markov model that simulated the natural history of disease and the impact of screening. A lifetime horizon was considered. The authors stated that a societal perspective was adopted in the study.
Effectiveness data:
The authors stated that the epidemiological data used in the model were based on official public health reports or published studies, such as the Italian Ministry of Health or the provincial administrative database of diagnosis-related groups in the Veneto region (where the study took place). Data on disease progression were taken from other published evidence, details of which were not reported. Treatment effectiveness was based on the results from randomised clinical trials (RCTs). Some assumptions about the compliance of individuals were also made.
Monetary benefit and utility valuations:
Utility valuations were based on published studies, details of which were not given. Utility weights were associated with each health state of the Markov model.
Measure of benefit:
The summary benefit measure was the quality-adjusted life-years. These were estimated using the decision model. The QALYs were discounted at an annual rate of 3%.
Results
In the IDU cohort (9,460 patients), the expected costs were EUR 153,165,347 with no screening and EUR 124,860,989 with screening. The expected QALYs were 413,848 (without screening) and 422,884 (with screening), respectively. Thus, the incremental analysis showed that screening was the dominant strategy (both more effective and less expensive). Similar findings were observed in the subgroup of patients with genotypes 1 and 4, while in the subgroup of patients with genotypes 2 and 3, the incremental cost per QALY of screening over no screening was EUR 9,659.
In the IWS cohort (4,738,313 patients), the expected costs were EUR 9,182,575 with no screening and EUR 913,831,278 with screening. The expected QALYs were 189,508,961 (without screening) and 189,509,954 (with screening), respectively. Thus, the incremental cost per QALY gained with screening was EUR 918,147 (EUR 699, 991 in the subgroup of genotypes 1 and 4; EUR 2,324,471 in the subgroup of genotypes 2 and 3).
In general, the sensitivity analysis corroborated the base-case finding, suggesting that screening was not cost-effective in the IWS cohort even when favourable assumptions were made. In the IDU cohort, screening was the preferred option at a prevalence of 10% or higher of genotypes 1 and 4.
